Evaluating alloimmunization risk in patients with sickle cell disease and in prenatal care patients with <scp> <i>RHCE</i> </scp> variants
The risk of developing anti-e or anti-hr<sup>B</sup> antibodies was low in patients with an RHCE*ceVS genotype, except in those with SCD. In patients with SCD, the presence of autoantibodies, recent transfusions and technical caveats complicate the assessment of clinical impact; therefore, an individualized evaluation of alloimmunization risk is recommended.
Authors
- Jessica Constanzo‐Yanez
- Nancy Robitaille
- Nadia Baillargeon (ORCID: https://orcid.org/0000-0003-3024-7170)
- Gabriel André Leiva‐Torres
Institutions
- Héma-Québec (CA)
- Centre Hospitalier Universitaire Sainte-Justine (CA)
Publication Details
- Journal
- Vox Sanguinis
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1111/vox.70193
- Primary Topic
- Blood groups and transfusion
- Type
- article
- Field-Weighted Citation Impact
- 0.00